Prurigo Nodularis Market

DelveInsight’s ‘Prurigo nodularis (PN)—Market Insights, Epidemiology and Market Forecast–2030’ report deliver an in-depth understanding of the Prurigo nodularis (PN), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.


The market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Prurigo nodularis (PN) market size from 2017 to 2030. The report also covers the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017–2030

Prurigo nodularis (PN) Disease Understanding and Treatment Algorithm

Prurigo nodularis (PN) Overview

Prurigo Nodules are cutaneous lesions often produced by repetitive scratching; hence the nickname “picker’s nodules,” which may occur as a sequel of chronic pruritus or neurotic excoriations. In 1909, Hyde and Montgomery first described PN with characteristic pruritic nodules on the extensor surfaces of the lower extremities in middle-aged women; later, the disease was reported in children’s and men also. The lesions are typically pruritic, resulting in an itch-scratch cycle that can be difficult to break and can occur in any age group. The pruritic condition disturbs the skin permeability, which makes it vulnerable to repeated scratching and itching with the entry of irritants and allergens. It is commonly associated with a variety of diseases, such as psychiatric disorders, atopic dermatitis, chronic renal failure, hyperthyroidism, iron-deficiency anemia, obstructive biliary disease, gastric malignancy, lymphoma, leukemia, human immunodeficiency virus (HIV), hepatitis B, and hepatitis C. Broadly, PN can be divided into atopic and nonatopic. The atopic condition is associated with an earlier age of onset and cutaneous hypersensitivity to various environmental allergens and presents in half of the Prurigo patients.


Pruritus as a symptom is present in many diseases, and a certain subset of patients may be predisposed to a higher sensitivity or lower tolerance to pruritus, developing a clinical prurigo response under the influence of the itch-scratch cycle. Resolution of the underlying etiology with eventual neuronal sensitization can ensue, leading to the perpetuation and spread of this secondary response. Although the evolution of this prurigo response is dependent on the underlying systemic illness-inducing CP, chronic scratching itself appears to alter the environment in the dermis and epidermis as evidenced by increased levels of neuropeptides and neurohyperplasia. It results in a chronic condition that may no longer be dependent on the underlying etiology that initially caused the CP.


Prurigo nodularis (PN) Diagnosis

PN is a clinical diagnosis, and patients will likely have a history of chronic pruritus with excoriations and flesh-colored, pink nodular lesions on extensor surfaces. It can be diagnosed clinically by visual examination, as these are large, more or less symmetrical nodules with intense itching. There are several conditions which resemble PN, such as Lichen planus, psoriasis, even eczema at times. The differential diagnoses are delineated in as some of the skin inflammatory conditions most closely linked with the PN.


Causes of chronic pruritus can be evaluated based on diagnostic tests, which includes a complete blood cell count (CBC), complete metabolic panel, thyroid studies including TSH and free T4, urinalysis, stool exam, HIV antibodies and chest x-ray. Besides, Tuberculin skin testing (Mantoux test), microscopy (Ziehl–Nielsen stain) and culture Indirect immunofluorescence, etc. can be recommended. The disease is sometimes diagnosed with a combination of clinical and histological evaluation.

Prurigo nodularis (PN) Treatment

PN is a challenging condition both for the patient and the doctor involved in the treatment process, and establishing treatments remain difficult due to the small amount of randomized clinical trials (RCTs) available. Generally, the therapies for PN aim to interrupt the vicious itch-scratch cycle. Besides, an individual treatment plan must consider age, underlying disease, comorbidities, severity, quality of life impairment, and expected side-effects. For better compliance and adherence, the various possibilities associated with the therapy, including its advantages and disadvantages, should be explained individually. Also, the treatment usually extends over a prolonged period that leads to severe mental and physical stress with too many treatment failures; thus, good long-term management of the patient is required.


Treatment is difficult, and due to the intensity of the itch, patients often go from doctor to doctor looking for relief. There is no one treatment which is always effective; thus, several treatments may need to be tried. Initial treatment is often potent prescription steroid creams. If it helps, a milder cream can be used for long-term control. Antihistamine creams (Zonalon, Pramoxine) or pills (Atarax, Periactin) are often added for additional relief. Intralesional steroid injections, antidepressant pills, and nonprescription capsaicin cream help many patients who show no improvement to the usual treatment. Severe and resistant cases can be controlled with cryotherapy (freezing the sores with liquid nitrogen spray), oral steroids or PUVA.


It covers the details of conventional and current medical therapies available in the Prurigo nodularis (PN) market for the treatment of the various types of PN. It also provides the treatment guidelines and algorithms of the United States and Europe. The DelveInsight’s Prurigo nodularis (PN) market report gives a thorough understanding of Prurigo nodularis (PN) by including details such as disease definition, causes, risk factors, pathogenesis, and diagnosis.

Prurigo nodularis (PN) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Diagnosed Prevalence of Prurigo nodularis, gender-specific diagnosed prevalence of prurigo nodularis, age-specific diagnosed prevalence of prurigo nodularis, type-specific prevalent population of prurigo nodularis, and severity-specific diagnosed prevalent population of prurigo nodularis in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030.

Key Findings

This section provides glimpses of the Prurigo nodularis epidemiology in the 7MM.

  • Prevalent population of Prurigo nodularis in 7MM is expected to increase at a CAGR of 0.63% for the study period, i.e., 2017–2030.
  • Among the 7MM countries in 2017, the United States accounted for the largest patient pool. On the other hand, Japan comprised the least number of cases affected by PN.
  • EU comprised ~38% of the patient pool for PN in 2017.
  • As per DelveInsight analysis, it has been observed that most of the patients with Prurigo nodularis diagnosed with atopic than non-Atopic.
  • Estimates reveal that the overall diagnosed prevalence of PN follows an increasing trend with an increase in severity of the symptoms, such that moderate cases account for maximum diagnosed prevalent cases, followed by severe and mild cases.

Country Wise-Prurigo nodularis (PN) Epidemiology

The epidemiology segment also provides the Prurigo nodularis (PN) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Prurigo nodularis (PN) Drug Chapters

The drug chapter segment of the Prurigo nodularis (PN) report encloses the detailed analysis of Prurigo nodularis (PN) and mid- and late-stage pipeline drugs. It also helps to understand the Prurigo nodularis (PN) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.

Prurigo nodularis (PN) Emerging Drugs

Serlopitant: Menlo Therapeutics

Serlopitant—also known as VPD-737—is an oral, small-molecule inhibitor with a novel mechanism of action, i.e., highly selective neurokinin 1 receptor (NK1-R) antagonist. With the selective inhibition of NK-1 signaling pathway, it is expected to suppress Prurigo nodularis and Pruritus conditions. The US FDA granted Breakthrough Therapy designation to serlopitant for the treatment of pruritus associated with PN.

Nalbuphine ER: Trevi Therapeutics

Nalbuphine ER is an oral extended-release opioid with a unique opioid receptor dual µ (mu) antagonist/κ (kappa) agonist mechanism of action. Based on the “opioid hypothesis” in itch, a drug with µ-opioid receptor antagonist or k-opioid receptor agonist properties would be expected to have antipruritic effects. The drug has a dual mechanism of action, acting as both an antagonist (blocker) to the body’s mu-opioid receptor and as an agonist (activator) to the kappa opioid receptor. The kappa and mu-opioid receptors are known to be critical mediators of the urges to scratch and cough, as well as of certain movement disorders. Nalbuphine’s mechanism of action also mitigates the risk of abuse associated with mu-opioid agonists because it blocks the mu-opioid receptor.

KPL-716: Kiniksa Pharmaceuticals

KPL-716, a monoclonal antibody inhibiting signaling through oncostatin M receptor beta (OSMRβ), is under development by Kiniksa Pharmaceuticals and being evaluated in patients with PN. The drug is first-in-class designed to inhibit signaling of interleukin-31 (IL-31) and oncostatin M (OSM), two key cytokines implicated in inflammation, pruritus, and fibrosis. The company believes KPL-716 is the only monoclonal antibody in development that simultaneously targets both pathways.

Dupixent (SAR231893): Sanofi/Regeneron Pharmaceuticals

Dupixent is a human monoclonal IgG4 antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling by specifically binding to the IL-4Rα subunit shared by the IL-4 and IL-13 receptor complex under development by Sanofi in collaboration with Regeneron Pharmaceutical. Dupixent is a fully human monoclonal antibody generated using the VelocImmune technology that is designed to bind to IL-4R alpha subunit and block signaling from both IL-4 and IL-13.

Products detail in the report…

Prurigo nodularis (PN) Market Outlook

Treatment of PN is challenging. The current market of PN can be classified based on the severity of the disease as mild, moderate, and severe. There is a multimodal treatment algorithm consisting of topical and systemic therapies, where topical therapies are used for treating the visible form of the disease. In contrast, systemic therapies are used for symptomatic treatment. The symptomatic therapy aims to reduce itching and complete healing of lesions. A mild form of the disease includes several topical therapies, such as antihistamines, topical corticosteroids, topical immunosuppressants, topical calcineurin inhibitors, emollients, which are recommended as both as basic therapy and general therapeutic measure. Due to the lack of approved therapeutic regimens for PN, management of the condition involves a multidisciplinary approach, including the maintenance of hygiene with minimal scratching. Both itch prevention and the complete healing of PN lesions are important to manage the disease. Proper education of the patients by explaining the underlying causes of pruritus is a must. Also, the psychological disorder which is associated with scratching and picking of skin should be addressed.


The PN market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted PN market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.


This segment gives a thorough detail of PN market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.


According to DelveInsight, Prurigo nodularis (PN) 7MM market is expected to change in the study period 2017–2030.

Key Findings

This section includes a glimpse of the Prurigo nodularis (PN) 7MM market.

  • The United States holds the highest market size of PN (52.31%) with USD 344.89 Million in 2017, which is expected to rise in the upcoming forecast period.
  • The market size of Prurigo nodularis in the seven major markets is USD 659.29 Million in 2017. 
  • Among the European countries, Germany accounts for the highest market share, followed by France and Spain holds the lowest market share in the 7MM.

7MM Market Outlook

This section provides the total Prurigo nodularis (PN) market size and market size by therapies in the United States, Germany, France, Italy, Spain, United Kingdom, and Japan.

Prurigo nodularis (PN) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs that are expected to get launched in the market during the study period 2017–2030. The analysis covers Prurigo nodularis (PN) market uptake by drugs; patient uptake by therapies; and sales of each drug.


This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Prurigo nodularis (PN) Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Prurigo nodularis (PN) emerging therapies.

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the Prurigo nodularis (PN) market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Prurigo nodularis (PN), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
  • Comprehensive insight has been provided into the Prurigo nodularis (PN) epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Prurigo nodularis (PN) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of Prurigo nodularis (PN) market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MMPrurigo nodularis (PN) market.

Report Highlights

  • Prurigo nodularis (PN) market is anticipated to increase at a CAGR of 12.98% for the study period 2017–2030.
  • The United States accounted for more than half (52.31%) of the market share in the 7MM.
  • Nemolizumab is projected to lead the market with the largest market share in 2030.
  • In the coming years, Prurigo nodularis (PN) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Prurigo nodularis (PN) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Prurigo nodularis (PN). Launch of emerging therapies will significantly impact the Prurigo nodularis (PN) market.
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key competitors, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Prurigo nodularis (PN) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Prurigo nodularis (PN) Pipeline Analysis
  • Prurigo nodularis (PN) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Prurigo nodularis (PN) Report Key Strengths

  • Eleven Years Forecast
  • 7MM Coverage
  • Prurigo nodularis (PN) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Prurigo nodularis (PN) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Number of Companies:

  • Menlo Therapeutics: Serlopitant
  • Trevi Therapeutics : Nalbuphine ER
  • Galderma: Nemolizumab
  • Sanofi/Regeneron: Dupixent
  • Kiniksa Pharmaceuticals: KPL-716
  • Amgen: Apremilast
  • Maruho: M118103

Key Questions

Market Insights:

  • What was the Prurigo nodularis (PN) market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Prurigo nodularis (PN) total market size as well as market size by therapies across the 7MM during the forecast period (2020–2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Prurigo nodularis market size during the forecast period (2020–2030)?
  • At what CAGR, the Prurigo nodularis (PN) market is expected to grow at the 7MM level during the forecast period (2020–2030)?
  • What would be the Prurigo nodularis (PN) market outlook across the 7MM during the forecast period (2020–2030)?
  • What would be the Prurigo nodularis (PN) market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of Prurigo nodularis (PN)?
  • What is the historical Prurigo nodularis (PN) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Prurigo nodularis at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Prurigo nodularis (PN)?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Prurigo nodularis (PN) during the forecast period (2020–2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the treatment of Prurigo nodularis (PN) along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Prurigo nodularis (PN) in the US and Europe?
  • What are the Prurigo nodularis (PN) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Prurigo nodularis (PN)?
  • How many therapies are developed by each company for the treatment of Prurigo nodularis (PN)?
  • How many emerging therapies are in the mid-stage and late stage of development for the treatment of Prurigo nodularis (PN)?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Prurigo nodularis (PN) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Prurigo nodularis (PN) and their status?
  • What are the key designations that have been granted for the emerging therapies for Prurigo nodularis (PN)?
  • What are the 7MM historical and forecasted market of Prurigo nodularis (PN)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Prurigo nodularis (PN).
  • To understand the future market competition in the Prurigo nodularis (PN) market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Prurigo nodularis (PN) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for Prurigo nodularis (PN) market.
  • To understand the future market competition in the Prurigo nodularis (PN) market.

 

1 Key Insights

2 Prurigo nodularis (PN): Patient Overview at a Glance

2.1 Total Market Share (%) Distribution of PN in 2017

2.2 Total Market Share (%) Distribution of PN in 2030

3 Executive Summary

4 SWOT Analysis

5 Disease Background and Overview of Prurigo nodularis (PN)

5.1 Introduction

5.2 Classification

5.3 Clinical Signs and Symptoms

5.4 Pathophysiology

5.5 Etiology

5.5.1 Skin Disorders

5.5.2 Systemic Disorders

5.5.3 Psychiatric disorders

5.5.4 Associated Conditions

5.6 Diagnosis

5.7 Management

6 Recognized Establishments

7 Epidemiology and Patient Population: Prurigo nodularis (PN)

7.1 Key Findings

7.2 Epidemiology Methodology

7.3 KOL Views

7.4 7MM Total Diagnosed Prevalent Population of Prurigo nodularis

8 Country-wise Epidemiology of Prurigo nodularis

8.1 United States

8.1.1 Assumptions and Rationale

8.1.2 Diagnosed Prevalence of Prurigo nodularis in the United States

8.1.3 Gender-specific Diagnosed Prevalence of Prurigo nodularis in the United States

8.1.4 Age-specific Diagnosed Prevalence of Prurigo nodularis in the United States

8.1.5 Type-specific Diagnosed Prevalent Population of Prurigo nodularis in the United States

8.1.6 Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in the United States

8.2 EU5 Countries

8.2.1 Assumptions and Rationale

8.3 Germany

8.3.1 Diagnosed Prevalence of Prurigo nodularis in Germany

8.3.2 Gender-specific Diagnosed Prevalence of Prurigo nodularis in Germany

8.3.3 Age-specific Diagnosed Prevalence of Prurigo nodularis in Germany

8.3.4 Type-specific Diagnosed Prevalent Population of Prurigo nodularis in Germany

8.3.5 Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in Germany

8.4 France

8.4.1 Diagnosed Prevalence of Prurigo nodularis in France

8.4.2 Gender-specific Diagnosed Prevalence of Prurigo nodularis in France

8.4.3 Age-specific Diagnosed Prevalence of Prurigo nodularis in France

8.4.4 Type-specific Diagnosed Prevalent Population of Prurigo nodularis in France

8.4.5 Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in France

8.5 Italy

8.5.1 Diagnosed Prevalence of Prurigo nodularis in Italy

8.5.2 Gender-specific Diagnosed Prevalence of Prurigo nodularis in Italy

8.5.3 Age-specific Diagnosed Prevalence of Prurigo nodularis in Italy

8.5.4 Type-specific Diagnosed Prevalent Population of Prurigo nodularis in Italy

8.5.5 Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in Italy

8.6 Spain

8.6.1 Diagnosed Prevalence of Prurigo nodularis in Spain

8.6.2 Gender-specific Diagnosed Prevalence of Prurigo nodularis in Spain

8.6.3 Age-specific Diagnosed Prevalence of Prurigo nodularis in Spain

8.6.4 Type-specific Diagnosed Prevalent Population of Prurigo nodularis in Spain

8.6.5 Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in Spain

8.7 United Kingdom

8.7.1 Diagnosed Prevalence of Prurigo nodularis in the United Kingdom

8.7.2 Gender-specific Diagnosed Prevalence of Prurigo nodularis in the United Kingdom

8.7.3 Age-specific Diagnosed Prevalence of Prurigo nodularis in the United Kingdom

8.7.4 Type-specific Diagnosed Prevalent Population of Prurigo nodularis in the United Kingdom

8.7.5 Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in the United Kingdom

8.8 Japan

8.8.1 Assumption and Rationale

8.8.2 Diagnosed Prevalence of Prurigo nodularis in Japan

8.8.3 Gender-specific Diagnosed Prevalence of Prurigo nodularis in Japan

8.8.4 Age-specific Diagnosed Prevalence of Prurigo nodularis in the Japan

8.8.5 Type-specific Diagnosed Prevalent Population of Prurigo nodularis in Japan

8.8.6 Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in Japan

9 Treatment

9.1 Topical and intralesional therapy

9.1.1 Phototherapy/excimer

9.1.2 Systemic therapy

9.1.3 Novel treatments

9.1.4 Oral Immunosuppressant

9.1.5 Surgical Care for PN

9.1.6 Psychosomatic Therapy

9.2 Treatment algorithm

10 European Guidelines on PN

10.1 General principles

10.2 General measures

10.3 Causative therapy and etiology specific treatment

10.3.1 Symptomatic therapy: Topical

10.4 Systemic therapy

11 FDA Recommendations for PN Treatment

11.1 Diagnostic workup

11.2 Treatment Recommendations

12 Unmet Need

13 Emerging Drugs

13.1 Key Competitors

13.2 Serlopitant: Menlo Therapeutics

13.2.1 Product Description

13.2.2 Other Developmental Activities

13.2.3 Clinical Development

13.2.4 Safety and Efficacy

13.2.5 Product Profile

13.3 Nalbuphine ER: Trevi Therapeutics

13.3.1 Product Description

13.3.2 Other Development Activities

13.3.3 Clinical Development

13.3.4 Safety and Efficacy

13.3.5 Product Profile

13.4 Nemolizumab (CD14152): Galderma

13.4.1 Product Description

13.4.2 Other Development Activities

13.4.3 Clinical Development

13.4.4 Safety and Efficacy

13.4.5 Product Profile

13.5 Apremilast (CC-10004): Amgen

13.5.1 Product Description

13.5.2 Other Development Activities

13.5.3 Clinical Development

13.5.4 Safety and Efficacy

13.5.5 Product Profile

13.6 M 118103: Maruho

13.6.1 Product Description

13.6.2 Other Development Activities

13.6.3 Clinical Development

13.6.4 Clinical Trials Information

13.6.5 Product Profile

13.7 KPL-716: Kiniksa Pharmaceuticals

13.7.1 Product Description

13.7.2 Other Developmental Activities

13.7.3 Clinical Development

13.7.4 Safety and Efficacy

13.7.5 Product Profile

13.8 Dupixent (Dupilumab/SAR231893): Sanofi/Regeneron Pharmaceuticals

13.8.1 Product Description

13.8.2 Other Developmental Activities

13.8.3 Clinical Development

13.8.4 Product Profile

14 Market Size: Prurigo nodularis

14.1 Key Findings

14.2 Market Methodology

14.3 KOL Views

14.4 Total Market Size of Prurigo nodularis (PN) in the 7MM

14.5 Total Market Size of Prurigo nodularis (PN) by therapies in the 7MM

15 Attribute Analysis

16 Conjoint Analysis

17 7MM Market Outlook

17.1 United States

17.1.1 Total Market size of Prurigo nodularis (PN) in the United States

17.1.2 Total Market Size of Prurigo nodularis (PN) by Therapies in the US

18 EU5 Countries

18.1 Germany

18.1.1 Total Market size of Prurigo nodularis (PN) in Germany

18.1.2 Total Market Size of Prurigo nodularis (PN) by Therapies in Germany

18.2 France

18.2.1 Total Market size of Prurigo nodularis (PN) in France

18.2.2 Total Market Size of Prurigo nodularis (PN) by Therapies in France

18.3 Italy

18.3.1 Total Market size of Prurigo nodularis (PN) in Italy

18.3.2 Total Market Size of Prurigo nodularis (PN) by Therapies in Italy

18.4 Spain

18.4.1 Total Market size of Prurigo nodularis (PN) in Spain

18.4.2 Total Market Size of Prurigo nodularis (PN) by Therapies in Spain

18.5 United Kingdom

18.5.1 Total Market size of Prurigo nodularis (PN) in the UK

18.5.2 Total Market Size of Prurigo nodularis (PN) by Therapies in the UK

19 Japan

19.1 Total Market size of Prurigo nodularis (PN) in Japan

19.2 Total Market Size of Prurigo nodularis (PN) by Therapies in Japan

20 Case Reports

20.1 Chronic Prurigo: An Unusual Presentation of Hodgkin Lymphoma

20.2 Recalcitrant prurigo nodularis treated successfully with Dupilumab

20.3 Recurrent prurigo nodularis related to infected tonsils

21 Market Drivers

22 Market Barriers

23 Appendix

24 Report Methodology

25 DelveInsight Capabilities

26 Disclaimer

27 About DelveInsight

List of Tables

 Table 1: Summary of Prurigo nodularis, Epidemiology, and Key Events (2017–2030)

Table 2: Differential diagnosis of PN

Table 3: Total Diagnosed Prevalent Population of Prurigo nodularis in the 7MM (2017–2030)

Table 4: Diagnosed Prevalence of Prurigo nodularis in the United States (2017–2030)

Table 5: Gender-specific Diagnosed Prevalence of Prurigo nodularis in the United States (2017–2030)

Table 6: Age-specific Diagnosed Prevalence of Prurigo nodularis in the United States (2017–2030)

Table 7: Type-specific Prevalent Population of Prurigo nodularis in the United States (2017–2030)

Table 8: Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in the United States (2017–2030)

Table 9: Diagnosed Prevalence of Prurigo nodularis in Germany (2017–2030)

Table 10: Gender-specific Diagnosed Prevalence of Prurigo nodularis in Germany (2017–2030)

Table 11: Age-specific Diagnosed Prevalence of Prurigo nodularis in Germany (2017–2030)

Table 12: Type-specific Prevalent Population of Prurigo nodularis in Germany (2017–2030)

Table 13: Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in Germany (2017–2030)

Table 14: Diagnosed Prevalence of Prurigo nodularis in France (2017–2030)

Table 15: Gender-specific Diagnosed Prevalence of Prurigo nodularis in France (2017–2030)

Table 16: Age-specific Diagnosed Prevalence of Prurigo nodularis in France (2017–2030)

Table 17: Type-specific Prevalent Population of Prurigo nodularis in France (2017–2030)

Table 18: Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in France (2017–2030)

Table 19: Diagnosed Prevalence of Prurigo nodularis in Italy (2017–2030)

Table 20: Gender-specific Diagnosed Prevalence of Prurigo nodularis in Italy (2017–2030)

Table 21: Age-specific Diagnosed Prevalence of Prurigo nodularis in Italy (2017–2030)

Table 22: Type-specific Prevalent Population of Prurigo nodularis in Italy (2017–2030)

Table 23: Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in Italy (2017–2030)

Table 24: Diagnosed Prevalence of Prurigo nodularis in Spain (2017–2030)

Table 25: Gender-specific Diagnosed Prevalence of Prurigo nodularis in Spain (2017–2030)

Table 26: Age-specific Diagnosed Prevalence of Prurigo nodularis in Spain (2017–2030)

Table 27: Type-specific Prevalent Population of Prurigo nodularis in Spain (2017–2030)

Table 28: Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in Spain (2017–2030)

Table 29: Diagnosed Prevalence of Prurigo nodularis in the United Kingdom (2017–2030)

Table 30: Gender-specific Diagnosed Prevalence of Prurigo nodularis in the United Kingdom (2017–2030)

Table 31: Age-specific Diagnosed Prevalence of Prurigo nodularis in the United Kingdom (2017–2030)

Table 32: Type-specific Prevalent Population of Prurigo nodularis in the United Kingdom (2017–2030)

Table 33: Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in the United Kingdom (2017–2030)

Table 34: Diagnosed Prevalence of Prurigo nodularis in Japan (2017–2030)

Table 35: Gender-specific Diagnosed Prevalence of Prurigo nodularis in Japan (2017–2030)

Table 36: Age-specific Diagnosed Prevalence of Prurigo nodularis in Japan (2017–2030)

Table 37: Type-specific Prevalent Population of Prurigo nodularis Japan (2017–2030)

Table 38: Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in Japan (2017–2030)

Table 39: Stepwise treatment approach for chronic nodular prurigo

Table 40:General measures for treating PN

Table 41:Evidence-based therapies for PN

Table 42: Comparison of emerging drugs under development

Table 43:Serlopitant, Clinical Trial Description, 2020

Table 44:Nalbuphine ER, Clinical Trial Description, 2020

Table 45:Nemolizumab (CD14152), Clinical Trial Description, 2020

Table 46:Apremilast (CC-10004), Clinical Trial Description, 2020

Table 47:M 118103, Clinical Trial Description, 2020

Table 48: KPL-716, Clinical Trial Description, 2020

Table 49:Dupilumab (SAR231893), Clinical Trial Description, 2020

Table 50: Total Market Size of Prurigo nodularis (PN) in the 7MM in USD Million (2017–2030)

Table 51: Total Market Size of PN by Therapies in the 7MM in USD Million (2017–2030)

Table 52: Conjoint Analysis for Nemolizumab

Table 53: Conjoint Analysis for Dupixent

Table 54: Conjoint Analysis for Vixarelimab

Table 55: Conjoint Analysis for Nalbuphine ER

Table 56: Conjoint Analysis for Serlopitant

Table 57: Total Market size of Prurigo nodularis (PN) in the US (2017–2030)

Table 58: Total Market Size of PN by Therapies in the US, in USD Million (2017–2030)

Table 59: Total Market size of Prurigo nodularis (PN) in Germany (2017–2030)

Table 60: Total Market Size of PN by Therapies in Germany, in USD Million (2017–2030)

Table 61: Total Market size of Prurigo Nodularis (PN) in France (2017–2030)

Table 62: Total Market Size of PN by Therapies in France, in USD Million (2017–2030)

Table 63: Total Market size of Prurigo nodularis (PN) in Italy (2017–2030)

Table 64: Total Market Size of PN by Therapies in Italy, in USD Million (2017–2030)

Table 65: Total Market size of Prurigo nodularis (PN) in Spain (2017–2030)

Table 66: Total Market Size of PN by Therapies in Spain, in USD Million (2017–2030)

Table 67: Total Market size of Prurigo nodularis (PN) in the UK (2017–2030)

Table 68: Total Market Size of PN by Therapies in the UK, in USD Million (2017–2030)

Table 69: Total Market size of Prurigo Nodularis (PN) in Japan (2017–2030)

Table 70:Total Market Size of PN by Therapies in Japan, in USD Million (2017–2030) 

List of Figures

 Figure 1: Prurigo nodularis (PN) SWOT Analysis

Figure 2: PN - Butterfly Sign – No lesion on the center of the back

Figure 3: Symptoms of PN

Figure 4: A section showing orthohyperkeratosis, hypergranulosis, elongation of the rete ridges, vertical arrangement of collagen fibers, and an increased number of capillaries.

Figure 5: Total Diagnosed Prevalent Patient Population of Prurigo nodularis in the 7MM (2017–2030)

Figure 6: Diagnosed Prevalence of Prurigo nodularis in the United States (2017–2030)

Figure 7: Gender-specific Diagnosed Prevalence of Prurigo nodularis in the United States (2017–2030)

Figure 8: Age-specific Diagnosed Prevalence of Prurigo nodularis in the United States (2017–2030)

Figure 9: Type-specific Prevalent Population of Prurigo nodularis in the United States (2017–2030)

Figure 10: Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in the United States (2017–2030)

Figure 11: Diagnosed Prevalence of Prurigo nodularis in Germany (2017–2030)

Figure 12: Gender-specific Diagnosed Prevalence of Prurigo nodularis in Germany (2017–2030)

Figure 13: Age-specific Diagnosed Prevalence of Prurigo nodularis in Germany (2017–2030)

Figure 14: Type-specific Prevalent Population of Prurigo nodularis in Germany (2017–2030)

Figure 15: Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in Germany (2017–2030)

Figure 16: Diagnosed Prevalence of Prurigo nodularis in France (2017–2030)

Figure 17: Gender-specific Diagnosed Prevalence of Prurigo nodularis in France (2017–2030)

Figure 18: Age-specific Diagnosed Prevalence of Prurigo nodularis in France (2017–2030)

Figure 19: Type-specific Prevalent Population of Prurigo nodularis in France (2017–2030)

Figure 20: Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in France (2017–2030)

Figure 21: Diagnosed Prevalence of Prurigo nodularis in Italy (2017–2030)

Figure 22: Gender-specific Diagnosed Prevalence of Prurigo nodularis in Italy (2017–2030)

Figure 23: Age-specific Diagnosed Prevalence of Prurigo nodularis in Italy (2017–2030)

Figure 24: Type-specific Prevalent Population of Prurigo nodularis in Italy (2017–2030)

Figure 25: Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in Italy (2017–2030)

Figure 26: Diagnosed Prevalence of Prurigo nodularis in Spain (2017–2030)

Figure 27: Gender-specific Diagnosed Prevalence of Prurigo nodularis in Spain (2017–2030)

Figure 28: Age-specific Diagnosed Prevalence of Prurigo nodularis in Spain (2017–2030)

Figure 29: Type-specific Prevalent Population of Prurigo nodularis in Spain (2017–2030)

Figure 30: Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in Spain (2017–2030)

Figure 31: Diagnosed Prevalence of Prurigo nodularis in the United Kingdom (2017–2030)

Figure 32: Gender-specific Diagnosed Prevalence of Prurigo nodularis in the United Kingdom (2017–2030)

Figure 33: Age-specific Diagnosed Prevalence of Prurigo nodularis in the United Kingdom (2017–2030)

Figure 34: Type-specific Prevalent Population of Prurigo nodularis in the United Kingdom (2017–2030)

Figure 35: Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in the United Kingdom (2017–2030)

Figure 36: Diagnosed Prevalence of Prurigo nodularis in Japan (2017–2030)

Figure 37: Gender-specific Diagnosed Prevalence of Prurigo nodularis in Japan (2017–2030)

Figure 38: Age-specific Diagnosed Prevalence of Prurigo nodularis in Japan (2017–2030)

Figure 39: Type-specific Prevalent Population of Prurigo nodularis in Japan (2017–2030)

Figure 40: Severity-specific Diagnosed Prevalent Population of Prurigo nodularis in Japan (2017–2030)

Figure 41: Treatment algorithm of PN

Figure 42: Unmet Needs of PN

Figure 43: Total Market Size of Prurigo nodularis (PN) in the 7MM in USD Million (2017–2030)

Figure 44: Total Market Size of PN by therapies in the 7MM in USD Million (2017–2030)

Figure 45: Market size of Prurigo nodularis (PN) in the US (2017–2030)

Figure 46: Total Market Size of PN by Therapies in the US, in USD Million (2017–2030)

Figure 47: Market size of Prurigo nodularis (PN) in Germany (2017–2030)

Figure 48: Total Market Size of PN by Therapies in Germany, in USD Million (2017–2030)

Figure 49: Market size of Prurigo nodularis (PN) in France (2017–2030)

Figure 50: Total Market Size of PN by Therapies in France, in USD Million (2017–2030)

Figure 51: Market size of Prurigo nodularis (PN) in Italy (2017–2030)

Figure 52: Total Market Size of PN by Therapies in Italy, in USD Million (2017–2030)

Figure 53: Market size of Prurigo nodularis (PN) in Spain (2017–2030)

Figure 54: Total Market Size of PN by Therapies in Spain, in USD Million (2017–2030)

Figure 55: Market size of Prurigo nodularis (PN) in the UK (2017–2030)

Figure 56: Total Market Size of PN by Therapies in the UK, in USD Million (2017–2030)

Figure 57: Market size of Prurigo nodularis (PN) in Japan (2017–2030)

Figure 58: Total Market Size of PN by Therapies in Japan, in USD Million (2017–2030)

Figure 59: Market Drivers

Figure 60:Market Barriers

• Menlo Therapeutics: Serlopitant

• Trevi Therapeutics : Nalbuphine ER

• Galderma: Nemolizumab

• Sanofi/Regeneron: Dupixent

• Kiniksa Pharmaceuticals: KPL-716

• Amgen: Apremilast

• Maruho: M118103

  • Tags:
  • Prurigo Nodularis market
  • Prurigo Nodularis market research
  • Prurigo Nodularis market insight
  • Prurigo Nodularis market trends
  • Prurigo Nodularis market forecast
  • Prurigo Nodularis market share
  • Prurigo Nodularis pipeline drugs
  • Prurigo Nodularis treatment algorit...
  • Prurigo Nodularis drugs
  • Prurigo Nodularis sales forecasting
  • Prurigo Nodularis market size
  • Prurigo Nodularis disease
  • Prurigo Nodularis epidemiology
  • Prurigo Nodularis

Forward to Friend

Need A Quote